Breast Cancer Steering Committee

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

The NCI Breast Cancer Steering Committee (BCSC) was established in September 2008. At monthly meetings, it addresses the design, prioritization, and evaluation of concepts for phase 2 and phase 3 treatment trials in adult breast cancer. View the BCSC member roster.

Strategic Priorities

  • BCSC Strategic Priorities were formulated with the goal that the majority of submitted concepts would align with these established priorities. They address areas of unmet clinical need, important unanswered clinical questions, and potential new approaches to disease treatment.

Breast Oncology Local Disease (BOLD) Task Force

  • BOLD was established to provide early input into concepts for studies of localized breast cancer treated with surgery or radiation therapy prior to review by the BCSC. One of BOLD’s projects was to develop case report forms specific for localized breast cancer trials. If you need help accessing the case report forms, view our step-by-step instructions.

Clinical Trials Planning Meetings (CTPMs)

CTPMs are held periodically and focus on specific clinical trial related topics. The following are important BCSC CTPMs:

  • Life Style Intervention for Improving Disease-Free Survival in Early Stage Invasive Breast Cancer
    Several small studies suggested that a lifestyle intervention including exercise and weight loss might improve disease-free survival in women with invasive breast cancer. To address this topic in detail, in February 2014, a 1.5-day meeting resulted in the development of a trial, the Breast Cancer WEight Loss Study (BWEL Study), which is currently enrolling patients. Read the executive summary. Learn more about the study.
  • Next Generation Trials for Estrogen Receptor (ER) Positive Breast Cancer
    Although estrogen receptor (ER)-positive breast cancer has a relatively good 5-year prognosis, patients continue to relapse over time, making ER-positive breast cancer the majority of breast cancer deaths and thus in need of new clinical trials. The goals of the meeting were to address strategies to improve outcomes from clinical trials of any class of treatment in any stage of ER-positive breast cancer with a scientific focus on overcoming mechanisms of resistance to hormonal therapy. The May 2012 CTPM developed common definitions/clinical classification for endocrine resistance considering early stage and metastatic disease. It also concluded that standardized guidance on biopsies (compulsory and non-compulsory) and specimen storage is needed. Read the executive summary.
  • Next Generation Trials for HER2 Positive Breast Cancer
    HER2-positive breast cancers, about 15 - 20% of breast cancers, are generally more aggressive, respond less to hormone therapy, and are more prone to recurrence. This May 2011 CTPM addressed which agent(s) should be tested in the next generation of phase II and III clinical trials and the need to develop a more complete understanding of the mechanisms of resistance to HER2-directed therapies. Read the executive summary.

Contact

For more information, contact Jennifer Hayes, Ph.D., at jennifer.hayes@nih.gov.

  • Updated: December 14, 2016